# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(5.52) per share which missed the analyst consensus estimate of $(0.23)...
Telesis Bio Inc. (the Company) (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate th...
Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in str...